Cipher Pharmaceuticals Inc has experienced a notable decline in stock value this week, amidst various operational updates and financial disclosures.
This week, Cipher Pharmaceuticals Inc (CPH.TO) saw its stock price drop by 5.34%, closing at C$13.69 on Tuesday. The company has been in the news for its recent financial results and legal victories, which may have influenced investor sentiment.
Advertisement
Cipher Pharmaceuticals Inc
CPH.TO
CPH.TO
Cipher Pharmaceuticals Inc
WealthAwesomeMarket cap
$346.92M
P/E
8.6x
52W high
$20.56
52W low
$12.48
1W change
-5.34%
Beta
0.40
Analyst Price Targets
Based on analyst covering CPH · as of Sep 23, 2026
Wall Street analysts forecast CPH stock price to rise 42.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$19.45
+42.5% Upside
Previously C$19.95 on Sep 17, 2026
Current Price
C$13.65
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CPH's historical volatility
30-Day Vol
24.1%
Annualized
90-Day Vol
46.4%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$11.42
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$12.86 | C$11.83 – C$13.98 |
| 60 trading days | C$12.12 | C$10.77 – C$13.63 |
| 90 trading days | C$11.42 | C$9.88 – C$13.19 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should consider the recent performance metrics and company updates while evaluating Cipher Pharmaceuticals, especially as it navigates both operational challenges and opportunities for growth.
Cipher Pharmaceuticals Reports 32% Decrease in Net Income for Q2 2026
Despite strong revenue growth in previous quarters, the recent financial results reveal a concerning downward trend in profitability.
Bull case
Cipher Pharmaceuticals has shown strong revenue growth in past quarters, indicating a solid business model. The confirmation of ownership over key clinical data may enhance its market position.
Bear case
The recent decline in net income and adjusted EBITDA points to potential challenges ahead. Additionally, the stock's performance below its moving averages suggests bearish sentiment.
Recent Price Action
Advertisement
This week, Cipher Pharmaceuticals Inc's stock has seen a decline, closing at C$13.69, down 1.73% on the day and 5.34% over the week. The stock has also decreased by 2.15% over the past month, reflecting a broader trend of underperformance for the year, with a year-to-date decline of 8.39%.
Company News and Developments
Cipher Pharmaceuticals has been active in the news recently, particularly regarding its financial performance. The company announced its Q2 2026 results, revealing a net income of $4.0 million, a decrease of 32% compared to the previous year. Additionally, Cipher secured a court confirmation of an arbitration award, affirming its ownership of key clinical data for Absorica LD in Canada. These developments may impact investor confidence and stock performance moving forward.
Technical Picture
From a technical standpoint, Cipher Pharmaceuticals is currently trading below both its 50-day moving average of C$15.12 and its 200-day moving average of C$15.98, indicating a bearish trend. The stock's 52-week range has been between C$12.48 and C$20.56, with the current price sitting at approximately 15% above its 52-week low. The beta of 0.40 suggests that the stock is less volatile than the broader market. The latest trading volume of 13,619 shares is notably higher than the 20-day average volume of 26,437 shares, indicating increased trading activity.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
